Acceptability, Barriers and Facilitators of a Communication Tool in Hospital Settings

December 3, 2024 updated by: Université de Sherbrooke

Acceptability of a Communication Tool Using Bedside Magnetized Posters, as Well as Barriers and Facilitators to Its Use.

The presence of appropriate systems to promote good communication within the care team is one of the ten important characteristics identified for effective interdisciplinary work. However, the current communication systems at the Eastern Townships University Health and Social Services Centre of the Sherbrooke University Hospital (SUH), an hospital setting in Sherbrooke (Quebec, Canada), are numerous, scattered and difficult to identify quickly. The bedside magnetized posters were developed to address this issue. The use of this kind of tool should improve teamwork, communication, and patient care. As the bedside magnetized posters are now well established on the stroke and geriatric units at the SUH, it is essential to evaluate their acceptability by staff members. In addition, identifying the barriers and facilitators to their use will support the team for eventual deployment in other care environments at the SUH.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The objectives of the study are:

  1. To describe the acceptability of magnetic posters by staff members in the Neurology Department - Stroke Unit, where they are already well established, and in the Geriatric Department, where they are newly introduced.
  2. To identify barriers and facilitators to the use of magnetic posters to assist the team in an eventual deployment in other care environments at SUH.

Methods

A mixed sequential design will be used (quantitative, qualitative and observational). The study population will be staff working with inpatients in the neurology-stroke and geriatric units of SUH. Staff meeting the eligibility criteria will be invited to complete an electronic survey on the acceptability of the magnetic posters. The survey will consist of 15 closed questions relating to the use of the magnetic posters (e.g. frequency of poster consultation) and its acceptability (e.g. ease of use, poster content), one open question to gather suggestions for improving the tool and 6 socio-demographic questions. The survey will take approximately 10-15 minutes to complete, and responses will be recorded on the Research Centre on Aging's RedCap server for later analysis.

Also, a member of the research team will carry out observations on the neurology-stroke and geriatric units for one half-day, in order to collect data concerning, among other things, how the posters are used (e.g. where are the posters available to staff, which posters are used) and the characteristics of the patients for whom the posters are used.

Finally, two semi-structured group interviews, one for the neurology-stroke unit and one for the geriatric unit, will be facilitated by a member of the research team. Each group will be made up of 6 to 8 employees from a variety of professions, in order to be representative of the population under study and will last 30-60 minutes. The focus groups will address the facilitators and barriers to poster use for each respective unit. Discussions will be recorded and verbatims will be kept for later analysis.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
41

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Canada
    • Quebec
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • CIUSSS de l'Estrie CHUS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study population will consist of staff members working with people hospitalized in the neurology-stroke and geriatric units of SUH. The sample will be made up of various types of professionals such as nurses, beneficiary attendants, physicians, residents, physiotherapists, occupational therapists, speech therapists, nutritionists, social workers, as well as people assigned to housekeeping and user transportation. If student nurses are present on these units at the time of recruitment, they may also be asked to participate.

Description

Inclusion Criteria:

  • adults aged 18 and over
  • employed by the SUH and working on stroke and geriatric units

Exclusion Criteria:

  • none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Staff on the neurology and geriatric units
Staff that will participate in the electronic survey (N=100) and focus group (N=6-8)
Other: focus group
Two semi-structured group interviews, lasting 30-60 minutes, on facilitators and barriers to poster use by staff members (N=6-8).
Other: electronic survey
An electronic survey of 15 closed questions on the acceptability of the magnetic posters (N=100).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Acceptability
Time Frame: From the time the participants begin the electronic survey to the time their answers are sent off (approx. 15 to 20 minutes). There are no cut-off points for this outcome
questions on acceptability of the magnetic posters will be asked in the electronic survey
From the time the participants begin the electronic survey to the time their answers are sent off (approx. 15 to 20 minutes). There are no cut-off points for this outcome
Barriers and facilitators
Time Frame: This outcome will be measured during the participants' focus group, which should have a duration of approx. 60 minutes. There are no cut-off points for this outcome
questions on barriers and facilitators to poster use will be asked during the focus group
This outcome will be measured during the participants' focus group, which should have a duration of approx. 60 minutes. There are no cut-off points for this outcome

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Questionnaire on the use of the magnetic posters
Time Frame: This outcome will be measured during the observational half-day, which should have a duration of approx. 4 hours. There are no cut-off points for this outcome
during the observational half-day, how the posters are used (where they are used and which posters are used) in the stroke and geriatric units will be collected
This outcome will be measured during the observational half-day, which should have a duration of approx. 4 hours. There are no cut-off points for this outcome
Characteristics of the patients
Time Frame: This outcome will be measured during the observational half-day, which should have a duration of approx. 4 hours. There are no cut-off points for this outcome
This outcome will be measured during the observational half-day, which should have a duration of approx. 4 hours.
This outcome will be measured during the observational half-day, which should have a duration of approx. 4 hours. There are no cut-off points for this outcome

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Université de Sherbrooke

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Fondation Vitae

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Marie-Helene Milot, PhD, Universite de Sherbrooke

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 17, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 5, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 5, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 30, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 8, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 14, 2023

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 5, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 3, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2024-5186

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Communication, Multidisciplinary

Clinical Trials on focus group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings